Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

@article{Kuenen2003PotentialRO,
  title={Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.},
  author={Bart C. Kuenen and Marcel Levi and Joost C M Meijers and Victor W. M. van Hinsbergh and Johannes Berkhof and Ajay Kakkar and Klaas Hoekman and Herbert M. Pinedo},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 11},
  pages={2192-8}
}
PURPOSE An increased incidence of thromboembolic events was observed during treatment with cisplatin-gemcitabine plus SU5416 (CG+SU5416), a tyrosine kinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor-1 and -2. Nine thromboembolic events occurred in eight of 19 patients. We performed an analysis of parameters of the coagulation cascade and vessel wall activation. MATERIALS AND METHODS Markers for thrombin generation and endothelial cell activation were measured… CONTINUE READING